EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 243 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Easing Concerns about Giving Research Study Participants Their Genetic Test Results June 1, 2018 EMA Recommends Granting a Conditional Marketing Authorisation for Epcoritamab August 17, 2023 Cancer in My Community: Addressing Health Disparities in Brazil July 18, 2023 Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... April 8, 2024 Load more HOT NEWS Newly Developed International Childhood Cancer Core Outcome Set Represents Physical, Psychosocial,... Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer. Dog Showers His Mom with Snuggles and Makes Her Laugh During... Keto Molecule Offers Clue for Preventing Colorectal Cancer
